Shesa's Investment Blog

What happened to Geron ( GERN )? Update : Today what happened to GERN was a U-turn. It crashed from $7.23 to $1.75 before bouncing back little bit and closed at $2.31. There were so many evidences of clinical trials going smooth, job postings for the drug, management confidence and almost everything was pointing towards a continued partnership collaboration with Johnson & Johnson 's Janssen Biotech. But Janssen said that it will terminate the partnership for cancer treatment drug imetelstat, after doing a strategic review of its portfolio to determine its highest priorities for future growth. As I wrote in my blog, with such negative news it could potentially come to $1. Today it opened around $1.75 and bounced back little bit and closed at $2.31. On the positive side, Geron said it plan on advancing imetelstat into a late-stage (Phase 3 trial) to evaluate the drug in patients with low or intermediate-1 risk myelodysplastic syndromes. This process i...

September 2018 - INVESTMENT BLOG By Shesa Nayak U.S. Stock Market Update U.S. Stock market is behaving as if it is immune to tariff and volatility as market keeps moving north. DOW, S&P 500 made all-time high on Friday as investors fears of full -blown trade war taking place decreased. NASDAQ had already reached to all time high a couple of weeks ago. The stock market rally is not a hype, rather it has been very substantive and robust. The economy remains strong, corporate earnings are robust, consumer spending may have taken a little pause but reminding the readers that holiday season is coming. Q3 earning season kicks-off in next 2-3 weeks which will be really exciting as we expect another round of blockbuster earnings from the corporate world. Tariff has no doubt created some hurdles for the stock market, but it has also created some terrific buying opportunities for some of the best Chinese companies. I will elaborate on these but...